Recently, MEDIROM Healthcare Technologies Inc. plans to acquire a majority stake in Japan Gene Medicine Corporation, a company engaged in prenatal diagnosis, providing genetic testing and analysis.
MEDIROM has signed a share transfer agreement to acquire 70% of the shares of Nippon Gene Medicine and has obtained an option to acquire the remaining 30%. The completion of these transactions is subject to certain conditions. Nippon Gene Medicine works with major hospitals in Japan to help medical professionals tailor delivery and treatment education based on the condition of the fetus. Unlike Europe and the United States, prenatal genetic testing services are not common in Japan.
Post time: Jul-15-2024
